The store will not work correctly when cookies are disabled.
N-(4-chlorophenyl)-3-(6-fluoro-1H-indazol-3-yl)benzenesulfonamide
ID: ALA4867966
PubChem CID: 164622333
Max Phase: Preclinical
Molecular Formula: C19H13ClFN3O2S
Molecular Weight: 401.85
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: O=S(=O)(Nc1ccc(Cl)cc1)c1cccc(-c2n[nH]c3cc(F)ccc23)c1
Standard InChI: InChI=1S/C19H13ClFN3O2S/c20-13-4-7-15(8-5-13)24-27(25,26)16-3-1-2-12(10-16)19-17-9-6-14(21)11-18(17)22-23-19/h1-11,24H,(H,22,23)
Standard InChI Key: KZSQYNDFBLBPPD-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 30 0 0 0 0 0 0 0 0999 V2000
12.4230 -15.2377 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.8451 -14.6599 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
11.6337 -15.4492 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
10.2259 -10.8298 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.2247 -11.6493 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.9328 -12.0583 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.9310 -10.4209 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.6396 -10.8262 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.6444 -11.6448 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.4244 -11.8933 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.9018 -11.2281 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.4167 -10.5688 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.6802 -12.6644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1351 -13.2748 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.3916 -14.0499 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.1927 -14.2158 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.7368 -13.6004 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4774 -12.8277 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.5180 -10.4214 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
11.0478 -14.4945 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.5040 -15.1044 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.7061 -14.9358 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.1625 -15.5450 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.4186 -16.3219 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.2235 -16.4862 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7636 -15.8758 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.8756 -16.9325 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 5 2 0
5 6 1 0
6 9 2 0
8 7 2 0
7 4 1 0
8 9 1 0
9 10 1 0
10 11 2 0
11 12 1 0
12 8 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 13 1 0
10 13 1 0
4 19 1 0
15 2 1 0
2 20 1 0
20 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 25 1 0
25 26 2 0
26 21 1 0
24 27 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 401.85 | Molecular Weight (Monoisotopic): 401.0401 | AlogP: 4.82 | #Rotatable Bonds: 4 |
Polar Surface Area: 74.85 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 7.75 | CX Basic pKa: 1.69 | CX LogP: 4.56 | CX LogD: 4.43 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.51 | Np Likeness Score: -2.13 |
References
1. Kwong AJ, Pham TND, Oelschlager HE, Munshi HG, Scheidt KA.. (2021) Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma., 12 (10.0): [PMID:34676038] [10.1021/acsmedchemlett.1c00376] |